Highlights
- Sigma Healthcare (ASX:SIG) reported AUD 10.8 billion in FY26 revenue.
- Normalised EBIT increased 20.6% to AUD 1.09 billion.
- Integration synergies reached AUD 32.6 million during FY26.
- Net Debt declined to AUD 663 million at year-end.
Sigma Healthcare Limited operates pharmacy retail, Franchise and wholesale distribution businesses following its combination with Chemist Warehouse Group. On November 16, 2026, Sigma Healthcare (ASX:SIG) was trading at AUD 2.90, up 0.35% during the session. The company’s first full financial year after the combination provides a basis for assessing sales performance, the integration programme and the contribution of Australian and international operations.
Pharmacy Retail and Wholesale Operations
Sigma (ASX:SIG) operates across pharmaceutical wholesaling, pharmacy support services and retail pharmacy networks. Its activities include supplying pharmaceutical products and supporting the Chemist Warehouse retail network. The Merger brought franchise and distribution activities together within an enlarged operating structure, making integration and consolidated segment reporting central to understanding the group.
The company reports Australian and international operating segments. Distribution capabilities, pharmacy relationships, retail execution and franchise arrangements play different roles in the business. Changes to these activities can affect both Revenue recognition and the margins reported across the combined operations. As a result, comparisons require attention to the reporting basis used by management.
FY26 Results and Integration Progress
In August 2026, Sigma (ASX:SIG) announced full-year results for the 12 months ended June 30, its first complete financial year following the merger. Revenue was AUD 10.8 billion, representing 15.5% growth against the normalised pro-forma comparison period. Normalised Earnings before interest and tax, or EBIT, rose 20.6% to AUD 1.09 billion, while the normalised EBIT Margin reached 10.1%.
Normalised net profit after tax increased 22.3% to AUD 732.3 million. These metrics are explicitly described by the company as normalised, and its percentage comparisons refer to the normalised pro-forma FY25 base. They should not be confused with an unadjusted historical comparison across two differently structured businesses.
Sigma (ASX:SIG) reported AUD 32.6 million of integration synergies delivered during FY26. The company retained an objective of AUD 100 million in annual synergies by FY29. Achieving that objective depends on continuing the integration programme, including practical delivery of operating efficiencies rather than merely identifying potential savings.
Regional Performance and Financial Position
Australia generated revenue growth of 14.9% and normalised EBIT growth of 18.3%. International segment EBIT increased 91.3% to AUD 55.8 million, with the company reporting that Ireland became profitable for the first time. Regional differences indicate that the pace of retail network development, operating costs and local market conditions matter to the consolidated outcome.
At June 2026 year-end, net debt stood at AUD 663 million. Sigma (ASX:SIG) reported a debt-to-normalised-EBITDA ratio of 0.57 times. Debt reduction and earnings expansion both affect this ratio, although reported Leverage measures do not eliminate exposure to funding costs, Working Capital requirements or Investment needs.
Risks and Points to Monitor
The merged group must coordinate large pharmacy networks and wholesale operations while maintaining Customer Service and Supply reliability. Integration expenditure, operational disruption, competitive pricing and regulatory settings affecting medicine distribution could influence results. The differences between normalised and statutory reporting also Warrant attention when comparing financial periods.
Future disclosures from Sigma (ASX:SIG) can be assessed for progress towards the FY29 synergy objective, Australian retail and distribution trends, international profitability and movements in net debt. Updates on margin performance will also help distinguish expansion in sales from changes in operating efficiency.
Key Insights
Sigma’s FY26 release showed higher revenue and normalised earnings in its first complete year after the Chemist Warehouse combination. Integration benefits, regional performance and leverage remain measurable indicators for subsequent reporting periods. Subsequent financial disclosures will help establish how the integration programme affects operating performance.






Please wait processing your request...